Physician profile
Michael Anthony Sim
NPI 1619743887
$1,804.24
in general payments reported to CMS, 2019-2025
16 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $530 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.24 |
| Education | $163.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $506.25 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $309.86 | 2025 | |
| Pfizer INC. | $198.22 | 2025 | |
| Madrigal Pharmaceuticals | $181.20 | 2025 | Rezdiffra |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $94.13 | 2024 | Entyvio |
| Qol Medical, LLC | $81.78 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $59.66 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $47.76 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.79 | 2024-2025 | Xifaxan |
| Shield Therapeutics INC | $31.09 | 2025 | |
| Genzyme Corporation | $28.58 | 2025 | |
| Celltrion USA INC. | $27.76 | 2025 | Vegzelma |
| Exact Sciences Corporation | $25.01 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $24.47 | 2024 | Dificid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $21.68 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.